Drug Combination Details
| General Information of the Combination (ID: C96055) | |||||
|---|---|---|---|---|---|
| Name | Pentagalloylglucose NP Info | + | 5-fluorouracil Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | C1D | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCNE1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | IFI27 | Molecule Info | |||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination significantly downregulated MDR1 and LRP1, suggesting the potential to reverse the resistance to 5-FU. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Inhibitory effects and molecular mechanisms of pentagalloyl glucose in combination with 5-FU on aggressive phenotypes of HepG2 cells. Nat Prod Res. 2021 Mar;35(5):815-818. | |||
